Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
This study was terminated on 29 September 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have participated in specific Phase 3 parent study
You may not be if
Failed screening for parent study, pregnant women, lactating mothers
Clareo Health | Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis
